Assessment of the efficacy of hydrogel-based wound dressing containing allantoin and silver nanoparticles in the treatment of second-degree burn wounds: A randomized clinical trial

开始日期2022-04-20

申办/合作机构

Mashhad University of Medical Sciences

NCT04101890

/ Terminated临床4期IIT

The Healthy Baby Bottoms Study: A Trial of Theraworx Foam Formulation for the Prevention and Treatment of Diaper Dermatitis

Diaper dermatitis is one of the most common dermatologic diseases affecting infants and children. The incidence is highest among those 9-12 months old and it has been reported to affect 7-50% of infants in the US. It is caused by skin exposure to a combination of several factors including: excessive moisture, topical irritants, reduced pH, friction, maceration and bacterial infection. When infants soil their diaper, diaper contents saturate the area raising the pH of the skin above the normal level of 5 or less, and leaving the area highly vulnerable to maceration from friction. Irritants in urine and feces are then able to penetrate the macerated skin, causing inflammation and greater skin friability. An elevation in the skin pH allows pathogenic bacteria to overgrow, and combined with the breakdown in the skin's outer epithelial barrier, can lead to bacterial infection. Theraworx Foam Formulation-Allantoin Liquid by Avadim Technologies, Inc. is a skin protectant with use for temporary protection of minor cuts, scrapes, burns and chapped or cracked skin. As such, Theraworx Foam used in the diaper area may be beneficial for protecting skin against diaper rash wounds, as well as for assisting with wound healing and reducing any associated pain. The purpose of this study is to determine caregivers' perceptions of the benefits of using Theraworx Foam on their infant's diaper area as part of their hygienic routine, including whether they feel the product is pleasant and easy to use, and whether they feel it helps prevent and reduce the severity of diaper dermatitis in their infants 1-14 months old.

开始日期2020-03-12

申办/合作机构

Children's National Research Institute

[+1]

100 项与尿囊素相关的临床结果

登录后查看更多信息

100 项与尿囊素相关的转化医学

登录后查看更多信息

100 项与尿囊素相关的专利（医药）

登录后查看更多信息

4,704

项与尿囊素相关的文献（医药）

2025-08-01·TALANTA

Development of a MS compatible HPLC-HILIC method for the analysis of allantoin and glycolic acid in snail slime and related dosage forms: Focus on the enantioseparation of allantoin

Article

作者: Carotti, Andrea ; Pagano, Cinzia ; Perioli, Luana ; Di Michele, Alessandro ; Bonafè, Samuele ; Protti, Michele ; Migni, Anna ; Mercolini, Laura ; Sardella, Roccaldo

Glycolic acid and allantoin are known to be responsible, at least in part, for the main activities of snail slime, such as moisturizing, skin regeneration, antioxidant, soothing and anti-inflammatory. Accordingly, a hydrophilic interaction liquid chromatography (HILIC) method for the analysis of allantoin and glycolic acid in snail slime samples was developed by a conventional UV-Vis detector and the diol-type Luna® HILIC column. An optimized eluent made up of acetonitrile/water/methanol/formic acid (90:5:5:0.1 v/v/v/v) allowed the separation of the two investigated compounds from each other and from lactic acid and hydantoin used as internal standards. Being allantoin a chiral compound, an enantioselective HPLC protocol was also developed. The chiral analysis of allantoin was performed with the Lux® 3 μm i-Amilose-3 chiral stationary phase using the same mobile phase as for the achiral analysis. The chiral method was efficiently transferred to a HPLC system coupled to triple-quadrupole mass spectrometry (MS/MS). HPLC-MS/MS analysis revealed the racemic nature of allantoin in the pure snail slime. The same profile was also observed in a prototype hydrogel prepared with snail slime. Moreover, the same method allowed to measure the amount of glycolic acid in the two investigated samples (pure snail slime and gel) and ascertain a valuable extraction recovery. The enantiomeric elution order (S)<(R) with the amylose-based phase was established coupling the results of experimental electronic circular dichroism analysis to time-dependent density functional theory simulations.

2025-08-01·AGRICULTURE ECOSYSTEMS & ENVIRONMENT

Feeding salicylates containing willow leaves to cattle modulates urea metabolism and mitigates urine-derived ammonia and nitrous oxide emissions from soil

作者: Dawid, Corinna ; Kuhla, Bjoern ; Wrage-Moennig, Nicole ; Goers, Solvig ; Mittermeier-Klessinger, Verena K. ; Mueller-Kiedrowski, Carolin B. M.

Ruminants on grazing lands have a great impact on ammonia (NH3) and nitrous oxide (N2O) emissions released from livestock productionWillow leaves are an established supplement in ruminant nutrition and are rich in salicylates and tannins, which may have a mitigating effect on NH₃ and N₂O emissions.We hypothesised that willow leaf supplementation in cattle nutrition affects nitrogen (N) and urea metabolism and mitigates urinary NH₃ and N₂O emissions from soil.Eight weaned Holstein bull calves were kept on pasture and supplemented with willow leaves or alfalfa hay in a crossover design.In a respiration chamber, feed intake, faeces and urine excretions were recorded and analyzed for total N and N-metabolites.Urea-N recycling was measured by the i.v. administration of a 13C urea tracer and a series of blood sampling.Cattle urine and artificial mimics supplemented with different salicylates were incubated with standard soil to measure NH₃ and N₂O and the N and O isotopic signatures.Despite a decline in urea turnover and N digestibility in rations supplemented with willow leaves, the leaves had no effect on microbial protein synthesis or the growth rate.Urine excretions with reduced urea but increased hippuric acid, phenolic acids, and salicylate concentrations in cattle fed willow leaves mainly inhibited bacterial denitrification processes involved in N₂O release from soil and mitigated NH₃ and N₂O emissions by 14 and 81%, resp.The results highlight intrinsic and extrinsic mechanisms that define both the nutritional significance and emission mitigation potential of supplementing cattle in pastures with willow leaves.

2025-06-01·JOURNAL OF FOOD SCIENCE AND TECHNOLOGY-MYSORE

Metabolomic profiling of colostrum bar for identification of functional compounds using high resolution mass spectroscopy

Article

作者: Tiwari, Shivam ; Rao, Vasundhara ; Poonia, Amrita

Graphical Abstract:

项与尿囊素相关的新闻（医药）

2025-05-22

·维健医药

WinHealth Pharma and Merz Upgrade Long-Term Partnership

SHANGHAI, May 19, 2025 – WinHealth Pharma Group (WinHealth Pharma) and Merz Therapeutics announced the signing of an enhanced long-term strategic partnership agreement, representing a significant milestone in their longstanding collaboration. This expanded agreement strengthens their strategic presence in the Greater China region and reaffirms their shared commitment to advancing access to innovative, high-quality therapies for a broader patient population.This strategic collaboration ushers in the next phase of partnership between WinHealth Pharma and Merz Therapeutics, advancing into the "2.0 Era". The collaboration has achieved a historic breakthrough in both depth and breadth. The partnership term has been substantially extended, and the product portfolio has been expanded from two to five key offerings, covering prescription medicines, over-the-counter (OTC) products, consumer health brands, and cross-border business. Furthermore, the geographic reach has been broadened from Mainland of China to China’s Hong Kong, Macau, and Taiwan, further extending access to innovative therapies for a larger patient population. This upgrade underscores the profound trust and mutual commitment between both companies, highlighting their unwavering dedication to sustainable, long-term growth in Greater China.At the strategic partnership signing ceremony, the leadership teams from WinHealth Pharma and Merz Therapeutics took a group photoThrough this collaboration, the two companies will further build on their successful partnership in Mainland of China, capitalizing on the proven success of Hepa-Merz® (Ornithine Aspartate Injection) and Contractubex® (Compound Heparin Sodium and Allantoin Gel), while expanding the commercialization rights of these products to China’s Hong Kong, Macau, and Taiwan. The partnership is further solidified with the introduction of new products, including the dermatology OTC brand Contractubex® (Compound Heparin Sodium and Allantoin Gel), PK-Merz® (Amantadine/Amantadine Sulfate) for Parkinson’s disease, and the renowned Pantogar® series for anti-hair loss. This strategic expansion further enriches and strengthens WinHealth Pharma’s portfolio, broadening its reach across prescription medicines, over-the-counter (OTC) products, and consumer health segments.• Hepa-Merz® (Ornithine Aspartate Injection): As an originator therapy, Hepa-Merz® is widely recommended by both domestic and international clinical guidelines as a first-line treatment for hepatic encephalopathy.• Contractubex® (Compound Heparin Sodium and Allantoin Gel): Known for its anti-inflammatory, moisturizing, and wound-healing properties, it is recommended in both domestic and international guidelines for the treatment of scars.• Contractubex® (Compound Heparin Sodium and Allantoin Gel): A leading OTC dermatology brand, Contractubex® Scar Gel is widely used in over 60 countries and is highly recommended by healthcare professionals for scar treatment.• PK-Merz® (Amantadine/Amantadine Sulfate): Used in the treatment of Parkinson’s disease, PK-Merz® helps improve motor symptoms by compensating for neurotransmitter imbalances in the brain and is effective in preventing and treating dyskinesia.• Pantogar® Series Anti-Hair Loss Products: Including capsules, shampoo, and tonic, these products enhance hair growth and provide essential nutrients, treating diffuse hair loss and supporting the natural growth of hair.This expanded collaboration not only solidifies WinHealth Pharma's leadership in the dermatology, hepatology, and neurology therapeutic areas but also injects new momentum into the company's strategic initiatives, driving its continued growth in Greater China and beyond.Andrea von der Lippe, President Region International Markets at Merz Therapeutics, said: "Since the inception of our partnership with WinHealth Pharma in 2017, we have achieved outstanding results. WinHealth Pharma has proven its exceptional commercialization capabilities, extensive market reach, and superior execution, establishing itself as a trusted long-term strategic partner. The deepening of this strategic collaboration not only builds on the strong foundation of our past successes but also paves the way for exciting new opportunities and broader development prospects in the Greater China market. We look forward to continuing our close collaboration with WinHealth Pharma to bring more established and innovative products to market, offering an even broader range of advanced therapeutic options for a wider patient base."Carlos Sese, Senior Director Head of Region APAC at Merz Therapeutics, said: "Our collaboration with WinHealth Pharma is built on a strong foundation of deep trust and a shared vision. We have maintained a close partnership and worked together to successfully bring several key products to market. The further deepening of this strategic partnership not only solidifies our position in Greater China but also opens up a new chapter for future business expansion and the introduction of innovative therapies. This upgrade of our strategic collaboration is not just an extension of our past successes, but a catalyst for unleashing our future potential. We look forward to continuing our close partnership with WinHealth Pharma, driving the development and commercialization of more groundbreaking therapies to meet the increasingly diverse treatment needs of patients."Jack Wang, Chairman of Hong Kong WinHealth Pharma Group, said: " The deepening of our strategic partnership with Merz Therapeutics is a landmark achievement, marking a new chapter in our collaboration across Greater China and unlocking unprecedented opportunities for growth. As a leading biopharmaceutical company with an integrated value chain, WinHealth Pharma remains committed to a patients-first philosophy, concentrating on the development and commercialization of innovative and originator drugs, while addressing the unmet medical needs in the healthcare sector. This strategic advancement will accelerate our market penetration and growth in Greater China, enhance our portfolio in critical therapeutic areas such as hepatology, neurology, and dermatology, driving our continued growth in Asia and global markets. Our unwavering commitment is to deliver groundbreaking therapies that significantly improve patient outcomes and quality of life, paving the way for a broader and brighter future."Oliver Hao, Executive Director and Co-CEO of Hong Kong WinHealth Pharma Group, said: "At WinHealth Pharma, we remain steadfast in our commitment to patients, partners, and employees, which is deeply rooted in our founding principles and corporate mission, driving our sustainable growth on a global scale continuously. This collaboration marks the commencement of a new ‘2.0 era’ in our strategic partnership with Merz Therapeutics. In this new model, both companies are committed to forging a deeper and more long-term collaboration that will not only benefit more patients across Greater China but will also significantly expand the reach and influence of the brands within the partnership’s scope. Moving forward, WinHealth Pharma remains focused on introducing more originator and innovative therapies, providing patients with more effective and accessible treatment options, enhancing their quality of life, and resolutely upholding our patient-centered development strategy."About Merz TherapeuticsMerz Therapeutics is dedicated to improving the lives of patients around the world. With its relentless research, development and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease and other health conditions that severely impact patients’ quality of life.Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.Please visit www.stage.merztherapeutics.com.About WinHealth PharmaFounded in 2006, WinHealth Pharma is a Hong Kong-based biopharmaceutical company with a comprehensive, end-to-end value chain. The company focuses on three core areas: proprietary pharmaceutical products, CSO business, and specialty care, with a strong commitment to the development and commercialization of cutting-edge medicines. Guided by a patient-first philosophy, we are dedicated to delivering breakthrough therapies and innovative healthcare solutions to patients with cardio-renal diseases, hematologic cancers, gastrointestinal diseases, respiratory and infectious diseases, rare diseases, and other unmet medical needs. Our commitment is to improve patients’ lives through transformative treatments. With a well-established presence in China, WinHealth Pharma is actively expanding across Asia and other international markets, building a comprehensive healthcare ecosystem, driving innovation, and addressing the evolving treatment needs of patients. For more information, please visit www.winhealth.hk.END

2025-05-06

·PRNewswire

Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)

First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S. MT PLEASANT, S.C., May 6, 2025 /PRNewswire/ -- Paradigm Therapeutics, Inc., a biopharmaceutical company, announces a $12.5 Million investment by Eshelman Ventures, LLC and appointment of Dr. Eshelman as a strategic advisor for Paradigm. SD-101 (Zorblisa™) is being developed as a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB) patients. Funds will be used to complete all activities to support an NDA submission in the later part of 2025. "We are excited about the opportunity to complete the development activities for SD-101 (Zorblisa™) and to move a path forward towards registration of this therapy for patients with all EB subtypes," said Robert Ryan., Ph.D., Chief Executive Officer of Paradigm Therapeutics. "There is a tremendous need for novel whole skin surface treatment options for treating the debilitating skin effects across all patients with Epidermolysis Bullosa. The Paradigm Therapeutics team will be working passionately to provide patients with a new therapeutic alternative in this disease with limited whole-body treatment options. Paradigm's goal is to provide this therapy to patients on a global basis and is working in parallel with potential partners to work towards this goal as quickly as possible." Dr. Ryan added, "Epidermolysis Bullosa is a devastating disease. We believe the clinical data show beneficial effects of the use of SD-101 across the range of EB patients, and strongly support progression towards registration. Results from the completed Phase II and Phase III trials indicate that SD-101 demonstrated a broad benefit with whole body treatment of the lesions and wounds on the entire skin surface in pediatric and adult patients across all EB patients, who have limited whole body treatment alternatives. Results also demonstrated that SD-101 has a favorable safety profile when used long term." "Eshelman Ventures is honored to invest in Paradigm Therapeutics and play a pivotal role in accelerating the development of SD-101 as a transformative treatment for Epidermolysis Bullosa," said Dr. Eshelman, founder of Eshelman Ventures. "As an investor and strategic advisor, I am deeply committed to working closely with this exceptional team as we work tirelessly to bring this innovative therapy to patients in need. The urgency of addressing the challenges faced by EB patients is what drives us; our goal is to provide an improved quality of life in this area of unmet need. Together, we will strive to revolutionize treatment options and make a meaningful impact on the lives of those affected by this debilitating disease." About Epidermolysis Bullosa (EB) Epidermolysis Bullosa is a rare, devastating genetic disorder causing very fragile skin that leads to severe skin blistering and open wounds often beginning at birth. There are no approved therapies that were developed to treat the entire skin surface of patients across all subtypes of EB patients, including wounds and lesional skin, which affects children and adults throughout their lifetimes. EB is a chronic disease, potentially disfiguring, and in some cases fatal. There are many genetic and symptomatic variations of EB, but all forms share the common symptom of fragile skin that blisters and tears, sometimes from the slightest friction or trauma. About SD-101 (Zorblisa™) SD-101 (Zorblisa™) is a topical cream that has demonstrated potential to provide improvement in treating the severe skin disruptions seen in patients across all EB subtypes. Phase II and Phase III studies were conducted in children and adults with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB. A total of 217 EB patients were included in these studies. SD-101 was applied topically over the entire body daily in adults and children as young as 21 days old for a period of three months. The primary outcome measurement was assessment of target wound closure, in addition to secondary measurements including reduction in body surface area (BSA) coverage of blisters and wounds. SD-101 (Zorblisa™) was the first EB treatment to receive the FDA's Breakthrough Therapy designation. SD-101 (Zorblisa™) received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) covering the broad treatment of EB. In addition to the Rare Pediatric Disease designation, SD-101 was granted Orphan Drug designation from the FDA and the European Commission (EC). Upon approval, Paradigm will be eligible to receive a Priority Review Voucher (PRV). About Paradigm Therapeutics, Inc. Paradigm Therapeutics, Inc. is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address critical medical needs in the treatment of rare diseases. Paradigm's main focus is the treatment of Epidermolysis Bullosa (EB). SD-101 (Zorblisa™), its leading therapy for the treatment of skin effects in patients with Epidermolysis Bullosa, has completed Phase II and Phase III clinical trials. SD-101 (Zorblisa™) is a topical cream that requires no special handling and can be stored at room temperature and has demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes. Forward Looking Statement Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Paradigm disclaims any intent or obligation to update these forward-looking statements. Company Contact Dr. Robert Ryan Chief Executive Officer [email protected] (919)-274-0703 Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期临床结果孤儿药突破性疗法临床2期

2025-05-06

·美通社

Paradigm宣布获得新投资

-Paradigm Therapeutics, Inc.宣布获得Eshelman Ventures, LLC投资，以支持完成SD-101（Zorblisa™）的开发——一种用于治疗所有亚型大疱性表皮松解症（EB）全皮肤表面的局部疗法首个用于治疗所有EB亚型患者全身皮肤表面伤口和病变的外用疗法资金将用于完成2025年下半年新药申请（NDA）所需全部工作及以及在美国的商业化计划南卡罗来纳州芒特普莱森特 2025年5月6日 /美通社/ -- 生物制药公司Paradigm Therapeutics, Inc.宣布获得Eshelman Ventures, LLC的1250万美元战略投资，并任命Eshelman博士为Paradigm的战略顾问。 SD-101（Zorblisa™）旨在开发成为首个针对所有大疱性表皮松解症（EB）亚型患者的全身外用治疗药物。本次融资将用于支持该药物在2025年下半年完成新药申请所需的全部工作。 Paradigm Therapeutics首席执行官Robert Ryan博士表示：“我们非常期待完成SD-101（Zorblisa™）的研发工作，并为所有EB亚型患者推进这一疗法的注册进程。当前亟需能够治疗所有大疱性表皮松解症患者皮肤损伤的创新全身皮肤表面治疗方案。 Paradigm Therapeutics将针对缺乏全身治疗选择的疾病，全力以赴为患者提供全新治疗方案。 Paradigm的目标是在全球范围内为患者提供这一疗法，并且目前正积极与潜在合作伙伴推进相关工作。” Ryan博士补充道：“大疱性表皮松解症是一种毁灭性的疾病。我们认为，现有临床数据表明SD-101对所有EB亚型患者显示出治疗获益，这为推进注册提供了有力支持。已完成II期和III期试验结果显示，SD-101在治疗成人和儿童EB患者全身皮肤表面的病变和伤口方面展现出广泛疗效，这些患者目前缺乏有效的全身治疗方案。结果还表明，长期使用SD-101具有良好的安全性。” Eshelman Ventures创始人Eshelman博士表示：“Eshelman Ventures很荣幸投资Paradigm Therapeutics，并在加速SD-101成为大疱性表皮松解症变革性疗法的过程中发挥关键作用。作为投资方和战略顾问，我将始终与这支优秀团队紧密合作，不懈努力，尽快为患者带来这一创新疗法。解决EB患者面临的挑战刻不容缓，这正是我们前行的动力；我们的目标是在这一亟待满足的医疗需求领域，改善患者的生活质量。我们将携手努力，革新治疗方案，为受这一顽疾困扰的患者的生活带来有意义的影响。” 关于大疱性表皮松解症（EB）大疱性表皮松解症是一种罕见的破坏性遗传疾病，患者皮肤极其脆弱，通常自出生起即出现严重水疱和开放性创面。目前尚无获批疗法可治疗所有EB亚型患者的全身皮肤表面，包括影响儿童和成人一生的伤口和病变皮肤。 EB是一种慢性疾病，可能导致毁容，严重时可危及生命。尽管EB存在多种基因型和临床表现，但所有患者都表现为皮肤极度脆弱这一共同特征——患者皮肤在轻微摩擦或外伤后就会出现水疱和撕裂。关于SD-101（Zorblisa™） SD-101（Zorblisa™）是一种外用乳霜，已证实具有改善所有EB亚型患者严重皮肤损伤的潜力。 II期和III期研究在患有单纯性、隐性营养不良（RDEB）或交界性EB的儿童和成人中开展。这些研究总共纳入了217名EB患者。成人和最小21天大的儿童每天全身外用SD-101，为期三个月。主要结果指标是目标伤口闭合情况的评估，此外还有次要指标，包括水泡和伤口的体表面积（BSA）覆盖范围的减少。 SD-101（Zorblisa™）是首个获得FDA突破性疗法认证的EB治疗药物。 SD-101（Zorblisa™）获得美国食品药品管理局（FDA）的罕见儿科疾病认定，适用范围覆盖EB的广泛治疗。除了罕见儿科疾病认定外，SD-101还获得了FDA和欧盟委员会（EC）的孤儿药认定。药物获批后，Paradigm将有资格获得优先审评券（PRV）。关于Paradigm Therapeutics, Inc. Paradigm Therapeutics, Inc.是一家私营临床阶段制药公司，专注于开发创新疗法，以满足罕见疾病治疗中的关键医疗需求。 Paradigm主要专注于大疱性表皮松解症（EB）的治疗。 SD-101（Zorblisa™）是其治疗大疱性表皮松解症患者皮肤效应的领先疗法，已完成II期和III期临床试验。 SSD-101（Zorblisa™）是一种外用乳霜，无需特殊处理，可常温保存，有望改善所有EB亚型患者的严重皮肤症状。前瞻性叙述除此处所载历史信息外，本新闻稿中讨论的事项均为前瞻性叙述，包含诸多风险和不确定性因素，包括：我们在产品开发、监管审批及商业化进程中对第三方的依赖；基于新技术开发候选产品固有的失败风险；临床开发投入相关的成本风险；以及其他风险。实际结果可能与预期存在重大差异。本前瞻性叙述仅代表本公司截至发稿时的判断。 Paradigm特此声明：本公司并无更新此前瞻性叙述的意图或义务。公司联系人 Robert Ryan博士首席执行官 rryan@paradigmtherapeutics.com (919)-274-0703

临床2期

100 项与尿囊素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00121	尿囊素	D02AX	DB11100

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
大疱性表皮松解	中国	江苏正大丰海制药有限公司	1982-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非Herlitz交界型表皮溶解水疱症	临床3期	美国	Scioderm, Inc.	2015-03-11
非Herlitz交界型表皮溶解水疱症	临床3期	澳大利亚	Scioderm, Inc.	2015-03-11
非Herlitz交界型表皮溶解水疱症	临床3期	奥地利	Scioderm, Inc.	2015-03-11
非Herlitz交界型表皮溶解水疱症	临床3期	法国	Scioderm, Inc.	2015-03-11
非Herlitz交界型表皮溶解水疱症	临床3期	德国	Scioderm, Inc.	2015-03-11
非Herlitz交界型表皮溶解水疱症	临床3期	以色列	Scioderm, Inc.	2015-03-11
非Herlitz交界型表皮溶解水疱症	临床3期	意大利	Scioderm, Inc.	2015-03-11
非Herlitz交界型表皮溶解水疱症	临床3期	立陶宛	Scioderm, Inc.	2015-03-11
非Herlitz交界型表皮溶解水疱症	临床3期	荷兰	Scioderm, Inc.	2015-03-11
非Herlitz交界型表皮溶解水疱症	临床3期	波兰	Scioderm, Inc.	2015-03-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02670330 (CTgov)	临床3期	大疱性表皮松解	152	SD-101 (SD-101-6.0 to SD-101-6.0)	淵夢夢壓淵鬱範鹹廠夢 = 鑰膚觸糧製繭壓衊餘憲遞簾顧廠願鹹遞夢膚衊 (夢蓋遞夢餘製窪襯膚鹹, 鑰壓鹹築構齋選膚鹽製 ~ 築壓壓觸夢繭憲獵壓鹽) 更多	-	2019-08-02
				Placebo (Placebo to SD-101-6.0)	淵夢夢壓淵鬱範鹹廠夢 = 艱築衊遞積窪製餘夢淵遞簾顧廠願鹹遞夢膚衊 (夢蓋遞夢餘製窪襯膚鹹, 鑰壓範築醖淵構艱鬱構 ~ 餘襯構齋觸願鬱餘構網) 更多
NCT02384460 (ESSENCE, CTgov)	临床3期	大疱性表皮松解 \| 非Herlitz交界型表皮溶解水疱症	169	SD-101-6.0 cream (SD-101-6.0 Cream)	糧鬱築淵選顧淵膚齋齋(構觸膚範顧糧憲蓋鹽鹽) = 觸製鏇積鹽窪繭醖鹹製選窪膚鹹憲衊蓋積築獵 (選糧選衊積積鏇襯蓋壓, 25.50) 更多	-	2018-10-16
				Placebo (SD-101-0.0) cream (Placebo (SD-101-0.0) Cream)	糧鬱築淵選顧淵膚齋齋(構觸膚範顧糧憲蓋鹽鹽) = 齋鹹齋淵觸壓簾憲膚憲選窪膚鹹憲衊蓋積築獵 (選糧選衊積積鏇襯蓋壓, 28.59) 更多